Building The Worm Atlas For I&I Breakthroughs

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.

Andrea Choe, CEO at Holoclara
Key Takeaways
  • Holoclara is developing therapeutics from worm secretions, aiming to modulate the immune system rather than suppress it.
  • The company is conducting a Phase I clinical trial for HC002, a worm-derived small molecule targeting eosinophilic esophagitis, with promising implications for broader immunology and inflammation treatments.
  • Holoclara's proprietary discovery engine and 'worm atlas' could lead to a new class of medicines, addressing various clinical concerns and potentially transforming patient care.

As Eureka moments go, Andrea Choe’s was very 21st century. Choe is the CEO and co-founder of Holoclara, a biotech start-up investigating a new class of medicines derived from intestinal worms

“Someone sent me this podcast about a guy who goes to Africa and walks around barefoot trying to get hookworms, on purpose, to treat his untreatable asthma,” Choe told In Vivo

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Science

More from Leadership